| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 2.1, positive 2.8, negative -0.7) on 20251031. The forces of Price Level (2), Sentiment towards Fundamentals (1.7), Option Speculation (1.5), Broad Market Trend (0.3), and Sector Price Trend (-0.3) will drive up the price. The forces of Valuation Sentiment (-1), and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (2.8). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-31 | 2% | 1.4% | 144.23 | 51 | -0.05% | 0.07% | 1.1 | -0.3 | 1.7 | 3.5 |
| 2025-10-30 | 3% | 1.3% | 144.3 | 52 | 0.17% | 0.14% | 1.1 | -0.4 | 2 | 4.9 |
| 2025-10-29 | 1% | 1% | 144.05 | 47 | -0.95% | 0.07% | 1.7 | -0.4 | 2.1 | -0.9 |
| 2025-10-28 | 2% | 1% | 145.44 | 74 | -0.65% | 0.21% | 1.8 | 0.2 | 2 | 5.2 |
| 2025-10-27 | 1% | 1% | 146.38 | 87 | 0.23% | 0.35% | 1.5 | 0.3 | 1.9 | 2.9 |
| 2025-10-26 | 1% | 1% | 1.3 | 0.4 | 2 | 1 | ||||
| 2025-10-25 | 0% | 0.9% | 1.3 | 0.4 | 2 | 0 | ||||
| 2025-10-24 | 1% | 0.9% | 146.05 | 79 | 0.01% | 0.28% | 1.4 | 0.4 | 2.2 | 0.9 |
| 2025-10-23 | 1% | 1% | 146.04 | 79 | 0.02% | 0.07% | 1.5 | 0.7 | 2.3 | 3.7 |
| 2025-10-22 | 1% | 1% | 146 | 79 | 0.65% | 0.14% | 1.3 | 0.7 | 2.3 | 1.2 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (-5) Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid Pfizer said Friday it filed a lawsuit against Metsera and Novo Nordisk saying Metsera breached its merger agreement obligations. (https://www.cnbc.com/) Fri. Oct 31, 2025 | |
| 2 (0) SNAP benefits expire, open enrollment, earnings: What to Watch Market Domination Overtime host Josh Lipton previews several of the biggest stories to come throughout next week, including: — The nearing expiration of SNAP benefits funding (Supplemental Nutrition Assistance Program) as a federal judge orders the Trump administration to continue funding the program. — Earnings results from Berkshire Hathaway (BRK-A, BRK-B) this Saturday and quarterly results from companies like Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Qualcomm (QCOM), and McDonald's (MCD) throughout the rest of the week — The beginning of open enrollment for health insurance coverage. — Economic commentary from a handful of Federal Reserve officials. — Tesla's (TSLA) shareholder meeting, where investors will vote on CEO Elon Musk's $1 trillion executive pay package. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime. (https://finance.yahoo.com/) Fri. Oct 31, 2025 | |
| 3 (8) Alphatec Shares Surge 22% Pre-Market On Lower Q3 Loss, Raised Outlook Alphatec Holdings, Inc. (ATEC) shares jumped more than 21% in pre-market trading on Friday after the medical technology company reported improved third-quarter results and raised its full-year outlook. (https://www.rttnews.com/) Fri. Oct 31, 2025 | |
| 4 (7) Pfizer Gets Nod to Proceed With Metsera Deal From US Regulators Pfizer Inc. said US regulators have cleared it to proceed with its offer to acquire obesity startup Metsera Inc., upping the pressure on Novo Nordisk A/S, which is attempting to make a rival bid. (https://www.bloomberg.com/) Fri. Oct 31, 2025 | |
| 5 (6) S&P 500 Gains and Losses Today: Amazon Stock Surges as Cloud Business Boosts Earnings; DexCom Drops The world's largest online retailer got a lift from its booming cloud computing business on Friday, Oct. 31, 2025, while a soft sales outlook weighed on a medical device firm's stock. (https://finance.yahoo.com/) Fri. Oct 31, 2025 | |
| 6 (9) Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on strong obesity drug momentum. (https://www.benzinga.com/) Fri. Oct 31, 2025 | |
| 7 (3) AbbVie raises full-year forecast, Newell Brands stock plunges Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including AbbVie (ABBV) shares sliding as the company raises its annual forecast on the success of its anti-inflammatory drugs, while Sharpie-parent company Newell Brands (NWL) stock plunges after cutting its full-year outlook on a challenging consumer environment tied to tariff price hikes. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. (https://finance.yahoo.com/) Fri. Oct 31, 2025 | |
| 8 (-7) Health insurance premiums rising for Main Street business owners, employees, with little relief in sight Health insurance premiums are rising across the U.S., and for small businesses on Main Streets across America, there's little relief for owners or employees. (https://www.cnbc.com/) Fri. Oct 31, 2025 | |
| 9 (6) Why Eli Lilly is making weight-loss pills before regulatory approval Eli Lilly (LLY) is producing weight-loss pills ahead of US approval to prepare inventory for when the product enters the market. Eli Lilly CFO Lucas Montarce talks to Yahoo Finance about Eli Lilly's expectations for the drug. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. (https://finance.yahoo.com/) Fri. Oct 31, 2025 | |
| 10 (8) 20% Earnings Growth Potential For DexCom, Analyst Cites Buying Opportunity DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead. (https://www.benzinga.com/) Fri. Oct 31, 2025 | |
| 11 (8) Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs The drugmaker hiked its guidance as sales soared for its popular weight-loss drugs Zepbound and Mounjaro. (https://www.investopedia.com/) Thu. Oct 30, 2025 | |
| 12 (8) Alignment Healthcare Reports Second Profitable Quarter By Taming Costs Alignment Healthcare reported its second consecutive profitable quarter in part by managing medical expenses better than many of its rivals who sell Medicare Advantage. (https://www.forbes.com/) Thu. Oct 30, 2025 | |
| 13 (1) Here's why Bristol Myers quarter wasn't enough to change our view on the stock The company's future hinges on the success of Cobenfy, the company's new schizophrenia drug. (https://www.cnbc.com/) Thu. Oct 30, 2025 | |
| 14 (8) We're raising our Eli Lilly price target — what a difference a quarter makes The drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications (https://www.cnbc.com/) Thu. Oct 30, 2025 | |
| 15 (-5) Cigna Forecasts Two-Year Margin Strain In Pharmacy Benefit Unit, Stock Tanks Cigna stock fell after Q3 results showed solid revenue but forecasted margin pressure in its pharmacy benefit services over the next two years. (https://www.benzinga.com/) Thu. Oct 30, 2025 | |
| 16 (8) Eli Lilly teams up with Walmart on Zepbound: CFO explains Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The pharmaceutical company also announced a partnership with Walmart (WMT) to make GLP-1s more accessible to consumers. Eli Lilly CFO Lucas Montarce joins Market Catalysts to discuss the pharmaceutical giant's earnings print and its Walmart partnership. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. (https://finance.yahoo.com/) Thu. Oct 30, 2025 | |
| 17 (7) Cardinal Health brings modernization and automation to the pharmaceutical supply chain Cardinal Health is charting the next chapter in pharmaceutical logistics with a major investment in modernizing and expanding its distribution network. Designed to improve efficiency, enhance customer responsiveness, and create safer, more supportive workplaces, these upgrades signal a new era in how pharmaceuticals and wellness products move through the supply chain. At the center of […] The post Cardinal Health brings modernization and automation to the pharmaceutical supply chain appeared fir (https://finance.yahoo.com/) Thu. Oct 30, 2025 | |
| 18 (8) Why Cardinal Health stock is up double-digits: CFO explains Cardinal Health (CAH) stock is climbing to a new record high after the company reported earnings results that beat on the top and bottom lines. Cardinal Health CFO Aaron Alt joins Market Catalysts to discuss the earnings print and the company's strategy for future growth. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. (https://finance.yahoo.com/) Thu. Oct 30, 2025 | |
| 19 (8) Bevel raises $10M Series A from General Catalyst for its AI health companion Bevel's AI health companion unifies data from wearables and daily habits across sleep, fitness, and nutrition into personalized insights. (https://finance.yahoo.com/) Thu. Oct 30, 2025 | |
| 20 (-6) Merck Cuts Top End of Sales Guidance, Misses on Keytruda Merck & Co. shaved the top end of its 2025 revenue guidance and failed to produce any standout sales beats for its medicines in the third quarter, adding to challenges the drugmaker is facing as it prepares for the loss of its star cancer drug Keytruda. (https://www.bloomberg.com/) Thu. Oct 30, 2025 | |
| 21 (3) We're trimming our position in this drugmaker that is up more than 4% Thursday The main story here remains Cobenfy, the company's new schizophrenia drug. (https://www.cnbc.com/) Thu. Oct 30, 2025 | |
| 22 (0) Unpacking the Latest Options Trading Trends in Eli Lilly (https://www.benzinga.com/) Thu. Oct 30, 2025 | |
| 23 (8) Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter. Separately, Danish drugmaker Novo Nordisk announced plans to buy Metsera Inc. in a deal that could be worth up to $9 billion. (https://finance.yahoo.com/) Thu. Oct 30, 2025 | |
| 24 (-5) Health-insurance premiums are soaring. How to tell if switching to a high-deductible plan during open enrollment is best for you. Premiums are on the rise and changes are coming to Obamacare insurance plans. (https://www.marketwatch.com/) Thu. Oct 30, 2025 | |
| 25 (7) Cigna Profits Hit Nearly $2 Billion Despite Rising Costs The Cigna Group reported third quarter net income of nearly $2 billion despite rising costs in the health plans it sells. (https://www.forbes.com/) Thu. Oct 30, 2025 | |
| 26 (8) Lilly Ups Guidance on Weight Loss, Obesity Drugs’ Strength Eli Lilly & Co. raised its full-year guidance as revenue from its blockbuster weight loss and diabetes drugs beat expectations in the third quarter and it started to show signs of cementing its lead against its biggest rival. (https://www.bloomberg.com/) Thu. Oct 30, 2025 | |
| 27 (6) Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of tariffs." (https://www.cnbc.com/) Thu. Oct 30, 2025 | |
| 28 (8) Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s. (https://www.cnbc.com/) Thu. Oct 30, 2025 | |
| 29 (2) UnitedHealth's $4.3 Billion Profit Fueled By 'Generosity Of Uncle Sam,' Says Healthcare Activist: Government Drives 78% Of Health Plan Revenue Managed care company UnitedHealth Group Inc. reported $113 billion in revenue, up 12% year-over-year, and a profit of $4.3 billion. (https://www.benzinga.com/) Thu. Oct 30, 2025 | |
| 30 (5) Alphabet, Eli Lilly and Estee Lauder rise premarket; Meta, Microsoft fall Alphabet, Eli Lilly and Estee Lauder rise premarket; Meta, Microsoft fall (https://www.investing.com/) Thu. Oct 30, 2025 | |
| 31 (8) Eli Lilly raises annual revenue guidance amid strong weight-loss drug demand Eli Lilly raises annual revenue guidance amid strong weight-loss drug demand (https://www.investing.com/) Thu. Oct 30, 2025 | |
| 32 (8) Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares higher. (https://finance.yahoo.com/) Thu. Oct 30, 2025 | |
| 33 (9) Eli Lilly raises full-year forecast, as weight-loss drugs demand drives third-quarter beat () -Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro helped it beat third-quarter earnings estimates. The company shares jumped 7% in premarket trading. (https://finance.yahoo.com/) Thu. Oct 30, 2025 | |
| 34 (2) Novo and Pfizer Square Off Over Metsera in Obesity-Drug Tussle Novo offered to buy the company, Metsera Inc., for at least $6.5 billion, seeking to trump an earlier agreed deal with Pfizer. Metsera called the new offer superior to the previous one from Pfizer, which it had accepted last month. Pfizer countered that Novo’s attempt to derail the deal is “reckless” and an attempt to abuse its dominant market position. (https://finance.yahoo.com/) Thu. Oct 30, 2025 | |
| 35 (8) Eli Lilly’s stock jumps as Zepbound sales nearly triple at lower prices Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook. (https://www.marketwatch.com/) Thu. Oct 30, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA